<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02229812</url>
  </required_header>
  <id_info>
    <org_study_id>135.313</org_study_id>
    <nct_id>NCT02229812</nct_id>
  </id_info>
  <brief_title>Safe Implementation of Thrombolysis in Stroke - Monitoring Study</brief_title>
  <official_title>Safe Implementation of Thrombolysis in Stroke - Monitoring Study (SITS-MOST)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate the safety and efficacy of intravenous alteplase within 3 hours of symptom&#xD;
      onset in acute ischemic stroke patients&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2002</start_date>
  <primary_completion_date type="Actual">July 2006</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of symptomatic intracerebral hemorrhage (SICH)</measure>
    <time_frame>up to 36 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Independence for activities of daily living</measure>
    <time_frame>3 months</time_frame>
    <description>modified Ranking Scale 0-2</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">6475</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>thrombolytic therapy in stroke</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alteplase</intervention_name>
    <arm_group_label>thrombolytic therapy in stroke</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        acute stroke patients in the European Union&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female or male in-patient&#xD;
&#xD;
          -  Age 18 - 80 years&#xD;
&#xD;
          -  Clinical diagnosis of ischemic stroke causing a measurable neurological deficit&#xD;
             defined as impairment of language, motor function, cognition, gaze, vision and/or&#xD;
             neglect. Ischemic stroke is defined as an event characterized by sudden onset of acute&#xD;
             focal neurological deficit, presumed to be caused by cerebral ischemia, after CT scan&#xD;
             exclusion of hemorrhage&#xD;
&#xD;
          -  Onset of symptoms within 3 hours prior to initiation of thrombolysis treatment&#xD;
&#xD;
          -  Stroke symptoms present for at least 30 minutes that had not significantly improved&#xD;
             before treatment. Symptoms must be distinguishable from an episode of generalized&#xD;
             ischemia (i.e. syncope), seizure, or migraine disorder&#xD;
&#xD;
          -  Patients are willing to receive thrombolysis treatment and to give informed consent&#xD;
             with regard to retrieval of data and follow up procedures, according to the&#xD;
             regulations in participating countries&#xD;
&#xD;
          -  Willingness and ability to comply with the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of intracranial hemorrhage (ICH) on the CT-scan&#xD;
&#xD;
          -  Symptoms of ischemic attack began more than 3 hours prior to infusion start or when&#xD;
             time of symptom onset is unknown&#xD;
&#xD;
          -  Minor neurological deficit or symptoms rapidly improving before start of infusion&#xD;
&#xD;
          -  Severe stroke as assessed clinically and/or by appropriate imaging techniques&#xD;
&#xD;
          -  Seizure at onset of stroke&#xD;
&#xD;
          -  Symptoms suggestive of subarachnoid hemorrhage, even if the CT-scan is normal&#xD;
&#xD;
          -  Administration of heparin within the previous 48 hours and a thromboplastin time&#xD;
             exceeding the upper limit of normal for laboratory&#xD;
&#xD;
          -  Patients with any history of prior stroke and concomitant diabetes&#xD;
&#xD;
          -  Prior stroke within the last 3 months&#xD;
&#xD;
          -  Platelet count of below 100,000/mm³&#xD;
&#xD;
          -  Systolic blood pressure &gt;185 mmHg or diastolic blood pressure &gt;110 mmHg, or aggressive&#xD;
             management (IV medication) necessary to reduce BP to these limits&#xD;
&#xD;
          -  Blood glucose &lt;50 or &gt; 400 mg/dl&#xD;
&#xD;
          -  Known hemorrhagic diathesis&#xD;
&#xD;
          -  Patients receiving oral anticoagulants, e.g. warfarin sodium&#xD;
&#xD;
          -  Manifest or recent severe or dangerous bleeding&#xD;
&#xD;
          -  Known history of or suspected intracranial hemorrhage&#xD;
&#xD;
          -  Suspected subarachnoid hemorrhage or condition after subarachnoid hemorrhage from&#xD;
             aneurysm&#xD;
&#xD;
          -  Any history of central nervous system damage (i.e. neoplasm, aneurysm, intracranial or&#xD;
             spinal surgery)&#xD;
&#xD;
          -  Hemorrhagic retinopathy, e.g. in diabetes (vision disturbances may indicate&#xD;
             hemorrhagic retinopathy)&#xD;
&#xD;
          -  Recent (less than 10 days) traumatic external heart massage, obstetrical delivery,&#xD;
             recent puncture of a non-compressible blood-vessel (e.g. subclavian or jugular vein&#xD;
             puncture&#xD;
&#xD;
          -  Bacterial endocarditis, pericarditis&#xD;
&#xD;
          -  Acute pancreatitis&#xD;
&#xD;
          -  Documented ulcerative gastrointestinal disease during the last 3 months, oesophageal&#xD;
             varices, arterial- aneurysm, arterial/venous malformation&#xD;
&#xD;
          -  Neoplasm with increased bleeding risk&#xD;
&#xD;
          -  Severe liver disease, including hepatic failure, cirrhosis, portal hypertension&#xD;
             oesophageal varices) and active hepatitis&#xD;
&#xD;
          -  Major surgery or significant trauma in past 3 months&#xD;
&#xD;
        All in- and exclusion criteria follow the summary of product characteristics of Actilyse®&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 28, 2014</study_first_submitted>
  <study_first_submitted_qc>August 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 1, 2014</study_first_posted>
  <last_update_submitted>August 28, 2014</last_update_submitted>
  <last_update_submitted_qc>August 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 1, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

